SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

BronchStop Study Protocol, Season 2.

O'Hagan, S; Cunningham, S; Drysdale, SB; Groves, HE; Hunt, S; Iskander, D; Liu, X; Lyttle, MD; Mpamhanga, CD; Waterfield, T; et al. O'Hagan, S; Cunningham, S; Drysdale, SB; Groves, HE; Hunt, S; Iskander, D; Liu, X; Lyttle, MD; Mpamhanga, CD; Waterfield, T; C Williams, T; Marlow, R; Roland, D (2025) BronchStop Study Protocol, Season 2. NIHR Open Res, 5. p. 85. ISSN 2633-4402 https://doi.org/10.3310/nihropenres.14097.2
SGUL Authors: Drysdale, Simon Bruce

[img] PDF Published Version
Available under License Creative Commons Attribution.

Download (969kB)

Abstract

INTRODUCTION: In 2021 we launched the BronchStart study, which collected information on 17,899 hospital attendances in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's (JCVI) decision to recommend the introduction of maternal respiratory syncytial virus (RSV) vaccination, which was rolled out in the United Kingdom in August/September 2024 for all pregnant women at a gestation of 28 weeks or more. That winter we performed the BronchStop study, which examined vaccine effectiveness in its first season, conducted a survey of mothers to understand factors affecting vaccine uptake, and collected RSV positive samples for molecular epidemiology. METHODS AND ANALYSIS: In the winter season of 2025-2026 we will conduct a UK-wide, multi-centre, prospective, test-negative case control study. The aim is to assess the effectiveness of maternal RSV vaccination against hospitalisation for RSV-associated acute lower respiratory tract infection (ALRI) amongst infants under the age of 6 months born to vaccine-eligible pregnant mothers. A survey designed in partnership with our public and patient involvement (PPI) group will be administered to mothers of recruited infants to understand factors affecting maternal vaccine uptake. RSV-positive samples will undergo whole genome sequencing, and all samples will undergo real-time, reverse transcriptase polymerase chain reaction (rRT-PCR) testing for a panel of respiratory viruses to understand residual causes of severe infant respiratory disease in the post-vaccination era. ETHICS AND DISSEMINATION: Participants recruited to the study will be asked for informed consent to participate in the maternal survey, for researchers to access their vaccination records, and for routinely collected virological samples from their infants to undergo rRT-PCR testing. Regular reports to advisory groups, including JCVI and the World Health Organisation, and for peer-reviewed publications are planned to disseminate findings and inform decision-making.

Item Type: Article
Additional Information: Copyright: © 2025 O'Hagan S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Respiratory syncytial virus; maternal vaccination; respiratory disease; infants
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: NIHR Open Res
ISSN: 2633-4402
Language: eng
Media of Output: Electronic-eCollection
Related URLs:
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
NIHR207417National Institute for Health and Care Researchhttps://doi.org/10.13039/501100000272
Dates:
Date Event
2025-12-02 Published Online
2025-11-27 Accepted
URI: https://openaccess.sgul.ac.uk/id/eprint/118439
Publisher's version: https://doi.org/10.3310/nihropenres.14097.2

Statistics

Item downloaded times since 03 Mar 2026.

Actions (login required)

Edit Item Edit Item